Article
Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer.
Chemotherapy - 1 Jan 2016
Tsuchiya Tomoshi, Arai Junichi, Matsumoto Keitaro, Miyazaki Takuro, Honda Sumihisa, Tagawa Tsutomu, Nakamura Akihiro, Taniguchi Hideki, Sano Isao, Akamine Shinji, Muraoka Masashi, Hisano Hiroshi, Yamasaki Naoya, Nagayasu Takeshi
Abstract excerpt
BACKGROUND: Postoperative 1-year administration of S-1, an oral derivative of 5-fluorouracil (5-FU), was shown to be feasible in lung cancer. The 5-year survival rates of postoperative patients treated with S-1 adjuvant chemotherapy and the prognostic impact of clinicopathological factors were examined. METHODS: The data of 50 patients with curatively resected pathological stage IB to IIIA non-small cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.